Photodynamic diagnosis for superficial bladder cancer: do all risk-groups profit equally from oncological and economic long-term results?
- PMID: 20689609
- PMCID: PMC2872595
- DOI: 10.4137/cmo.s1012
Photodynamic diagnosis for superficial bladder cancer: do all risk-groups profit equally from oncological and economic long-term results?
Abstract
Objective: Photodynamic diagnosis (PDD) of superficial bladder cancer decreases recurrence rates. We present oncological results of a randomized, prospective study, comparing transurethral resection (TUR) performed under conventional white light (WL) with PDD. The follow-up period is the longest reported to date. As costs might be reimbursed by prolonged recurrence-free survival in certain patients cost analysis in regard to risk-groups was performed.
Material and methods: Using chi-square test and log-rank test we compared recurrence rates of 103 patients after WL-TUR and of 88 patients after PDD-TUR. Cost analysis was performed according to risk-groups of recurrence.
Results: Mean follow-up was 99 months. Recurrence rate was 57% in WL vs. 28% in PDD (p < 0.001). Costs incurred by subsequent TUR averaged euro 2310 per WL patient vs. euro 713 per PDD patient. Savings per patient by PDD amounted to euro 1597. PDD costs were reimbursed in low, intermediate and high risk patients, respectively.
Conclusions: PDD-TUR is significantly superior to conventional WL-TUR in terms of recurrence rate. While economic benefit is most prominent in intermediate risk patients, PDD related costs are reimbursed in all risk-groups.
Keywords: cost analysis; photodynamic; recurrence rate; superficial bladder cancer; transurethral resection; urothelial carcinoma.
Figures


Similar articles
-
Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer.Int J Urol. 2024 Aug;31(8):876-885. doi: 10.1111/iju.15474. Epub 2024 Apr 30. Int J Urol. 2024. PMID: 38687165
-
Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis.Eur Urol. 2007 Jul;52(1):142-7. doi: 10.1016/j.eururo.2007.01.064. Epub 2007 Jan 22. Eur Urol. 2007. PMID: 17267099 Clinical Trial.
-
[Clinical experience with transurethral resection of bladder tumor (TUR-Bt) guided by photodynamic diagnosis (PDD)].Nihon Hinyokika Gakkai Zasshi. 2009 Nov;100(7):661-70. doi: 10.5980/jpnjurol.100.661. Nihon Hinyokika Gakkai Zasshi. 2009. PMID: 19999130 Japanese.
-
Time to Turn on the Blue Lights: A Systematic Review and Meta-analysis of Photodynamic Diagnosis for Bladder Cancer.Eur Urol Open Sci. 2021 Jul 22;31:17-27. doi: 10.1016/j.euros.2021.06.011. eCollection 2021 Sep. Eur Urol Open Sci. 2021. PMID: 34467237 Free PMC article. Review.
-
Novel Visualization Methods Assisted Transurethral Resection for Bladder Cancer: An Updated Survival-Based Systematic Review and Meta-Analysis.Front Oncol. 2021 Jul 13;11:644341. doi: 10.3389/fonc.2021.644341. eCollection 2021. Front Oncol. 2021. PMID: 34327134 Free PMC article.
Cited by
-
Image-Guided Transurethral Resection of Bladder Tumors - Current Practice and Future Outlooks.Bladder Cancer. 2017 Jul 27;3(3):149-159. doi: 10.3233/BLC-170119. Bladder Cancer. 2017. PMID: 28824942 Free PMC article. Review.
-
Review of current optical diagnostic techniques for non-muscle-invasive bladder cancer.Cent European J Urol. 2016;69(2):150-6. doi: 10.5173/ceju.2016.780. Epub 2016 Apr 15. Cent European J Urol. 2016. PMID: 27551551 Free PMC article. Review.
-
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.Nat Rev Urol. 2014 Oct;11(10):589-96. doi: 10.1038/nrurol.2014.245. Epub 2014 Sep 23. Nat Rev Urol. 2014. PMID: 25245244 Review.
-
The health economics of bladder cancer: an updated review of the published literature.Pharmacoeconomics. 2014 Nov;32(11):1093-104. doi: 10.1007/s40273-014-0194-2. Pharmacoeconomics. 2014. PMID: 25056838
-
Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.Cochrane Database Syst Rev. 2021 Dec 1;12(12):CD013776. doi: 10.1002/14651858.CD013776.pub2. Cochrane Database Syst Rev. 2021. PMID: 34850382 Free PMC article.
References
-
- Jichlinski P, Leisinger HJ. Fluorescence Cystoscopy in the Management of Bladder Cancer: A Help for the Urologist! Urol Int. 2005;74:97–101. - PubMed
-
- Zaak D, Karl A, Knüchel R, Stepp H, Hartmann A, Reich O, et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU International. 2005;96:217–22. - PubMed
-
- Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, Lumper W, et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology. 1994;44:836–41. - PubMed
-
- Jocham D. Photodynamic procedures in urology. Urologe (A) 1994;33:547–52. - PubMed
-
- Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Senkung des Rezidivrisikos oberflächlicher Harnblasenkarzinome mittels 5-Aminolävulinsäure-induzierter Fluoreszenzdiagnostik. Urologe (A) 2003;42:1366–73. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials